Myelodysplastic syndromes

Peter L. Greenberg; Eyal Attar; John M. Bennett; Clara D. Bloomfield; Uma Borate; Carlos M. De Castro; H. Joachim Deeg; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Steven D. Gore; David Head; Rami Komrokji; Lori J. Maness; Michael Millenson; Margaret R. O'Donnell; Paul J. Shami; Brady L. Stein; Richard M. Stone; James E. Thompson; Peter Westervelt; Benton Wheeler; Dorothy A. Shead; Maoko Naganuma

doi:10.6004/jnccn.2013.0104

Myelodysplastic syndromes

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O'Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. ThompsonPeter Westervelt, Benton Wheeler, Dorothy A. Shead, Maoko Naganuma

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.

Original language	English (US)
Pages (from-to)	838-874
Number of pages	37
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	11
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2013.0104
State	Published - Jul 1 2013
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2013.0104

Cite this

Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, R., Maness, L. J., Millenson, M., O'Donnell, M. R., Shami, P. J., Stein, B. L., Stone, R. M., ... Naganuma, M. (2013). Myelodysplastic syndromes. JNCCN Journal of the National Comprehensive Cancer Network, 11(7), 838-874. https://doi.org/10.6004/jnccn.2013.0104

Greenberg, PL, Attar, E, Bennett, JM, Bloomfield, CD, Borate, U, De Castro, CM, Deeg, HJ, Frankfurt, O, Gaensler, K, Garcia-Manero, G, Gore, SD, Head, D, Komrokji, R, Maness, LJ, Millenson, M, O'Donnell, MR, Shami, PJ, Stein, BL, Stone, RM, Thompson, JE, Westervelt, P, Wheeler, B, Shead, DA & Naganuma, M 2013, 'Myelodysplastic syndromes', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 7, pp. 838-874. https://doi.org/10.6004/jnccn.2013.0104

@article{3d16c3b8c5314c1b89945de7174d1c9e,

title = "Myelodysplastic syndromes",

abstract = "The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.",

author = "Greenberg, {Peter L.} and Eyal Attar and Bennett, {John M.} and Bloomfield, {Clara D.} and Uma Borate and {De Castro}, {Carlos M.} and Deeg, {H. Joachim} and Olga Frankfurt and Karin Gaensler and Guillermo Garcia-Manero and Gore, {Steven D.} and David Head and Rami Komrokji and Maness, {Lori J.} and Michael Millenson and O'Donnell, {Margaret R.} and Shami, {Paul J.} and Stein, {Brady L.} and Stone, {Richard M.} and Thompson, {James E.} and Peter Westervelt and Benton Wheeler and Shead, {Dorothy A.} and Maoko Naganuma",

year = "2013",

month = jul,

day = "1",

doi = "10.6004/jnccn.2013.0104",

language = "English (US)",

volume = "11",

pages = "838--874",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "7",

}

TY - JOUR

T1 - Myelodysplastic syndromes

AU - Greenberg, Peter L.

AU - Attar, Eyal

AU - Bennett, John M.

AU - Bloomfield, Clara D.

AU - Borate, Uma

AU - De Castro, Carlos M.

AU - Deeg, H. Joachim

AU - Frankfurt, Olga

AU - Gaensler, Karin

AU - Garcia-Manero, Guillermo

AU - Gore, Steven D.

AU - Head, David

AU - Komrokji, Rami

AU - Maness, Lori J.

AU - Millenson, Michael

AU - O'Donnell, Margaret R.

AU - Shami, Paul J.

AU - Stein, Brady L.

AU - Stone, Richard M.

AU - Thompson, James E.

AU - Westervelt, Peter

AU - Wheeler, Benton

AU - Shead, Dorothy A.

AU - Naganuma, Maoko

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.

AB - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.

UR - http://www.scopus.com/inward/record.url?scp=84882966505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882966505&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2013.0104

DO - 10.6004/jnccn.2013.0104

M3 - Article

C2 - 23847220

AN - SCOPUS:84882966505

SN - 1540-1405

VL - 11

SP - 838

EP - 874

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 7

ER -

Myelodysplastic syndromes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this